艾伯维 2024年度报告

People.Passion.Possibilities. 2024Annual Reporton Form 10-K 2025Notice of Annual Meeting& Proxy Statement Stockholder Information People are at the heart of every decision wemake at AbbVie. From discovery to delivery.From manufacturing to marketing. Eachdecision makes a difference. AbbVie Inc. Corporate Headquarters1 North Waukegan RoadNorth Chicago, IL 60064847-932-7900abbvie.com About our cover patient Investor RelationsDepartment ZZ05, AP34 “There’s a stigma around migraines, but don’t let that stopyou from getting treatment.” Corporate SecretaryDepartment V364, AP34 Dealing with debilitating migraines for most of her life,Alison tried many things.She’shopeful that with more timeand research, more can be doneto help her, and people likeher, live on their own terms. Stock Listing The ticker for AbbVie’s common stock isABBV. The principal market for the AbbViecommon stock is the New York StockExchange. AbbVie common stock is alsolisted on the Chicago Stock Exchange. Alison, ColoradoMigraine Annual Meeting The Annual Meeting will be held on Friday,May 9, 2025, at 9 a.m. CT. Please see theproxy statement for information about howto attend the virtual Annual Meeting. Dividend Reinvestment PlanThe AbbVie Dividend Reinvestment Plan offers registered stockholders anopportunity to purchase additional shares,commission-free, through automaticcash investments. Interested personsmay contact the transfer agent. Transfer AgentEQ Shareholder Services P.O. Box 64874St. Paul, MN 55164-0874www.shareowneronline.com877-881-5970651-450-4064 About AbbVie ~55Kemployees in morethan 70 countries ~175 countries where ourproducts help peopleand patients product or indicationapprovals in 2024** AbbVie’s mission is to discover anddeliver innovative medicines andsolutions that solve serious healthissues today and address the medicalchallenges of tomorrow. We strive to havea remarkable impact on people’s livesacross several key therapeutic areasincludingimmunology, oncology,neuroscience,and eye care—and productsand servicesin our Allergan Aestheticsportfolio. $10.8B*in adjusted R&Dinvestment in 2024 ~90active clinical anddevice programs >75conditions treated >235K For more information about AbbVie, pleasevisit us atabbvie.com. U.S. patients providedmedicine at no cost throughour patient assistanceprogram in 2024 *Reflects a non-GAAP measure and is adjusted for certainitems, which are reconciled in Appendix B Follow @abbvie on LinkedIn,Facebook, Instagram,X (formerly Twitter) and YouTube. **Compounds, devices or indications in developmentindividually or under collaboration or license agreements Dear Shareholders, AbbVie is embarking on a new phase of growth and 2024 was a year of significant progress.Rooted firmly in our core values and company principles, we remain dedicated to fostering a culture ofinnovation, excellence and patient-centricity. This commitment is what grounds us for future growth andwill enable AbbVie to deliver substantial shareholder returns. Over the past decade, we have increasedour quarterly dividend by more than 235% and expanded our market capitalization by $210 billion. I amconfident that our strategic direction and diverse portfolio will drive our growth in 2025 and beyond. AbbVie demonstrated strong performance in 2024, achieving total net revenues of $56.3 billion.We executed our top commercial priorities, advanced our pipeline and strengthened our businessthrough strategic transactions. Our five key areas — immunology, neuroscience, oncology, aestheticsand eye care — have allowed us to rapidly return to sales growth. Both Skyrizi and Rinvoq have performedexceptionally well, generating more than $17.6 billion in combined sales in 2024. Our oncologyportfolio recorded sales of $6.5 billion, while global net revenues from neuroscience approached$9 billion. The aesthetics portfolio contributed net revenues of nearly $5.2 billion. Our diversified growthplatform is on track to deliver robust mid-single-digit revenue growth in 2025. This will allow us tosurpass our previous peak revenue in just the second full year following the U.S. Humira loss ofexclusivity, an unprecedented feat in our industry. In 2024, we raised our adjusted R&D investment to $10.8 billion1. This has enabled advances inour pipeline with important regulatory approvals and promising data readouts across immunology,oncology, neuroscience and aesthetics. These include recent approvals for Skyrizi in ulcerative colitis,Epkinly in later lines of follicular lymphoma, Elahere for FR-alpha positive, platinum-resistant ovariancancer, Vyalev for advanced Parkinson’s disease, and new indications for Botox and Juvéderm. Wealso deepened our pipeline by entering into approximately 20 collaborations, licensing agreements orother asset acquisitions, and closing the ImmunoGen and Cerevel Therapeutics transactions. Our culture is a key contributor to our success. It unites us with a shared purpose and helps usstay true to